US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Processa Pharmaceuticals, Inc. - Common Stock (NQ:PCSA)

1.610 -0.010 (-0.62%)
Delayed Quote Updated: 3:56 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Processa Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Good morning! It's time to start the final day of trading this week with a look at the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 13 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 22 companies hit new 52-week lows. 
Via Benzinga
News headline image
Processa Pharma's Investigational Candidate Improves Gastroparesis-Associated Clinical Symptoms ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 11, 2022 ↗
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Biotech Showcase
Via Investor Brand Network
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 75 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 116 companies set new 52-week lows. 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Clinically Meaningful Improvements in Gastroparesis Symptoms
Via Investor Brand Network
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  Thursday's session saw 329 companies set new 52-week lows. 
Via Benzinga
News headline image
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
News headline image
Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Improved Gastric Emptying in Phase 2A Trial
Via Investor Brand Network
News headline image
PCS12852 Improves Gastric Emptying in Gastroparesis Patients
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Preview: Processa Pharmaceuticals ↗
Processa Pharmaceuticals (NASDAQ:PCSA) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q3 2022 Results, Provide Pipeline Update
Via Investor Brand Network
News headline image
Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Successful Results from NGC Phase 2B Trial
Via Investor Brand Network
News headline image
Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Update on Clinical Programs Enrollment
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Global Investment Conference
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Names New Key Board Appointments
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q2 2022 Results, Corporate Updates
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2022 Results Conference Call
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Launches New Website Focused on Rare Disease
Via Investor Brand Network
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >